Epsilon M&A Deal Report - Lab21
Transaction Multiples for the Valuation of Private Companies
Novacyt / Lab21
No EMAT :
68924
Announced Date :
27/05/2014
Type :
Exit ,Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Novacyt
Target :
Lab21
Country :
England
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Medical Diagnostic Laboratory
Business Description :
Founded in 2005, Lab 21 provides personalised diagnostic products and services to blood bank screening, medical diagnostics and drug discovery partners. > Operates through 2 divisions: Products:...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
ns | ns | ns | ns | ns | |
| Current |
|
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Medical Diagnostic Laboratory » = 55
| Date | Acquirer | Target | Country | Multiples | See details |
| 30/07/2012 | Fund raising led by Azulis Capital and Galia Gestion | SELAS Bio-Clinic | France | * | 68832 |
| 30/07/2014 | Labco | SDN (SDN Istituto di Ricerca Diagnostica e Nucleare) | Italy | ** | 68804 |
Source: Epsilon Research / EMAT
